Cyclerion Therapeutics
CYCNCyclerion Therapeutics is dedicated to advancing a new pipeline of therapeutics for neuropsychiatric diseases, with a primary focus on treatment-resistant depression (TRD). The company's strategy integrates therapies with validated mechanisms of action with a tech-enabled, personalized delivery system, aiming to create the first individualized treatment for TRD. Led by a team with deep experience in CNS drug development and commercialization, Cyclerion is positioned to address a significant market opportunity by targeting patients who have not responded to traditional antidepressant therapies. Their approach is grounded in clinical evidence and designed to maximize both safety and efficacy for this challenging patient population.
CYCN · Stock Price
Historical price data
AI Company Overview
Cyclerion Therapeutics is dedicated to advancing a new pipeline of therapeutics for neuropsychiatric diseases, with a primary focus on treatment-resistant depression (TRD). The company's strategy integrates therapies with validated mechanisms of action with a tech-enabled, personalized delivery system, aiming to create the first individualized treatment for TRD. Led by a team with deep experience in CNS drug development and commercialization, Cyclerion is positioned to address a significant market opportunity by targeting patients who have not responded to traditional antidepressant therapies. Their approach is grounded in clinical evidence and designed to maximize both safety and efficacy for this challenging patient population.
Technology Platform
A personalized therapeutic platform combining well-characterized anesthetic agents with a biofeedback-driven device system designed to reset dysregulated brainwave patterns in neuropsychiatric disorders.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Olinciguat + Matching Placebo | Achalasia | Phase 2 | |
| Matching Placebo + IW-1973 | Diabetes Mellitus, Type 2 | Phase 2 | |
| IW-1701 + Placebo | Sickle Cell Disease | Phase 2 | |
| IW-1973 + Placebo | Diabetes Mellitus, Type 2 | Phase 2 | |
| IW-1701 + Placebo | Healthy | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Competes against approved TRD therapies like Johnson & Johnson's Spravato (esketamine) and Axsome's Auvelity, as well as numerous companies developing psychedelic-based treatments and neuromodulation devices. Cyclerion's key differentiation is its personalized, biofeedback-driven delivery system designed to tailor therapy to individual brain physiology in real-time.